Gene test may help pick better donors for leukemia patients

NCT ID NCT02450708

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether choosing stem cell donors based on certain genes (KIR) in addition to standard matching can reduce the chance of leukemia returning after a bone marrow transplant. About 511 people with acute myeloid leukemia (AML) are taking part. Doctors will test donors for KIR genes and recommend the best match, but the final donor choice is up to the treating physician.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA

Contacts and locations

Locations

Baylor University Medical Center

Dallas, Texas, 75246, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Duke University Medical Center

Durham, North Carolina, 27701, United States
Hackensack University Medical Center Cancer Center

Hackensack, New Jersey, 07601, United States
Mayo Clinic Cancer Center

Rochester, Minnesota, 55905, United States
Md Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Ohio State University

Columbus, Ohio, 43210, United States
University of Washington School of Medicine

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.